Mike Carusi

Mike joined ATV in 1998 and focuses on investments in the life sciences and medical device sectors in the firm's Palo Alto, CA office. His representative investments include Altura Medical, Ardian (acquired by Medtronic), EndoGastric Solutions, GI Dynamics, GluMetrics, NeuroVista, Plexxikon (acquired by Daiichi Sankyo), PowerVision, TranS1 (NASDAQ: TSON), Second Genome, and MicroVention (acquired by Terumo). Featured on the 2011 Forbes Midas List of top technology investors, Mike is a recognized thought leader in the industry and a frequent speaker at healthcare-related conferences and trade shows. He serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum, sits on the Tuck MBA Advisory Board, and is an advisory board member to the UCSF/Berkeley Venture Innovation Program. Prior to joining ATV, Mike served as the Director of Business Development for Inhale Therapeutic Systems (now Nektar Therapeutics, NASDAQ: NKTR), a venture-backed pulmonary drug delivery company that went public in 1994. At Inhale, Mike led partnering activities with a number of well-established pharmaceutical and biotechnology companies in the U.S., Europe and Japan. Mike was also a Principal at The Wilkerson Group, a strategic ATV partner and leading management consulting firm focused exclusively on healthcare. At The Wilkerson Group, Mike helped establish the firm’s offices in London and San Francisco. Mike holds an M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College and a B.S. from Lehigh University.